- Brand names:
- Pharmaceutical Company:
- Condition/Indication: Cervical cancer
- Meeting Date: July 2022
- Public Summary Document (PSD) March 2022 PBAC Meeting - (PDF 1.3MB)
- Public Summary Document (PSD) March 2022 PBAC Meeting - (Word 514KB)
Cemiplimab – July 2022
Cemiplimab: Solution for I.V. infusion 350 mg in 7 mL; Libtayo®
Last updated
1 July 2022